Naturally Splendid Reports First Quarter Results for 2021

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the three months ended March 31, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid recorded a net loss and comprehensive loss of $743,636 for the three months ended March 31, 2021, compared to a net loss of $1,320,761 during the three months ended March 31, 2020. The decrease in net loss and comprehensive loss was attributed to the decrease in selling and distribution expenses. Revenues decreased by 5% over the same period last year and gross profit margins decreased to 13% of sales. The Company's sales decreased by approximately $467,000 from the comparative period. During the three-month period ended March 31, 2021, selling and distribution expense decreased by approximately $464,255 largely due to decreased in production (facility costs, quality assurance and lab testing) and production wages which were offset by the government wage subsidy received during the quarter. Administrative expenses decreased by approximately $190,325 predominantly from office, rent and salaries and corporate promotions. The decrease was attributed to a reduction in investor relations activity due to the pandemic and the reduction of corporate salaries from the government wage subsidy.

Naturally Splendid recorded sales of $253,378 during the three months ended March 31, 2021, compared to $720,255 in for three months ended March 31, 2020. The Company's sales decreased by approximately $467,000 from the comparative period which was attributed to decreased sales in its private label bars and bites business.

Cost of Sales during the three months ended March 31, 2021 was $221,587 compared to $593,626 in three months ended March 31, 2020. The Company gross margin percentage decreased to 13%, in the three months ended March 31, 2021.

The Company continued its sales mix with exports of bulk seed and launching its new plant-based products. The bulk hemp seeds sold at a lower gross margin percentage then compared to the plant-based products and private label sales. The Company is now focused on its higher margin products and new commercial opportunities. Gross profits for the three months ended March 31, 2021 was $31,791 (13% of sales) compared to $126,629 (18% of sales) for three months ended March 31, 2020. The best market opportunities for NSE have been both domestic and new international destinations along with Prosnack Natural Foods Inc. private label products.

For the Three Months Ended March 31, 2021For the Three Months Ended March 31, 2020
$$
Statements of Loss Data
Revenue
253,378720,255
Cost of sales
221,587593,626
Gross Profit
31,791126,629
Selling and distribution expenses
(140,166)(604,421)
Administrative expenses
(659,103)(862,864)
Other income(loss) and taxes
(743,636)(1,320,761)
Net income (loss)
(743,636)(1,320,761)
Basic and Diluted Earnings (Loss)
Per Share
(0.00)(0.01)

Naturally Splendid CEO Mr. J. Craig Goodwin reports, "The Company continues to focus on overall plant-based nutrition, health & wellness. The first quarter of 2021 was concentrated on establishing the foundation to our NATERATM Plant Based Foods opportunity. With sales of our premium bars sustaining significant setbacks in 2020 due directly to the pandemic, the Company took this opportunity to transition our primary focus to our NATERATM Plant Based Foods.

The Company has chosen to reduce its contract manufacturing clientele for bars and bites which in the short term has affected gross sales. Instead, the Company will put more emphasis on producing our own Company Brands that have greater margins.

Naturally Splendid continues to establish plant-based opportunities whether that be exports of bulk hemp to South Korea that has seen a recent resurgence, manufacturing bars and bites formulated for the sports and active lifestyle market, advancing the science of CavaltinibTM, the target drug approved by Health Canada for a phase 2 clinical trial for COVID, or driving business of our NATERATM Plant Based Foods through multiple distribution channels. Although diverse opportunities, the common denominator of these opportunities is all rooted in plant-based ingredients and products.

In particular, NATERATM Plant Based Foods are at the forefront of our efforts. In this regard, we have invested significantly in our NATERATM Plant Based Foods inventory and have established a comprehensive distribution network that covers Canada coast to coast. Distributors include CANEX Foods, Sysco, Gordon Food Service, Intercity Packers Meat and Seafood, Georgia Main Food Group, and others. This network of distributors provides access to thousands of clients across most every distribution channel including chain and independent retail stores as well as chain restaurants and individual locations.

The Company is leveraging our distributor network and developing relationships in the food service / restaurant channels for our NATERATM Plant Based Food line. With significant COVID restrictions being placed on the restaurant industry in particular, sales in this channel have been hindered. However, governments and health authorities have begun the process of relaxing many of these restrictions and we are confident the groundwork laid in this area will begin to provide a recurring revenue stream and we look forward to providing timely updates in this regard.

Efforts have been expended establishing new e-commerce strategies to support multiple online marketing initiates and our e-commerce sites are now operational. Our complete line of NATERATM Plant Based Foods including Plant-Based Burgers; Breaded Cutlets (Schnitzel); Garlicky Chick-Un Kiev; Sweet Chili Chick-Un Tenders; Seasoned Chick-Un Tenders; Chick-Un Nuggets; Chick-Un Patties; Crispy Fish-Un Fillets; Garlicky Chick-Un Bites and Cheesy Chick-Un Bites, are now available online.

Transitioning product mixes is not without challenge. However, we are confident the decisions that have been made to promote our own Company Brands and establishing NATERATM Plant Based Foods as our feature line will provide the foundation to growing shareholder value. We look forward to providing updates in a timely manner."

Naturally Splendid's financial statements can be viewed at: www.SEDAR.com

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-465-0548 (ext. 105)

On Behalf of the Board of Directors

Mr. J. Craig Goodwin

CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/649840/Naturally-Splendid-Reports-First-Quarter-Results-for-2021

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology .

About the Study

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less

Latest Press Releases

Related News

×